Osteoprotegerin and Osteopontin Levels, But Not Gene Polymorphisms, Predict Mortality in Cardiovascular Diseases

References

• Venuraju SM , YerramasuA, CorderR, LahiriA. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J. Am. Coll. Cardiol.55(19), 2049–2061 (2010).
   PubMed Web of Science ®Google Scholar
• Lieb W , GonaP, LarsonMGet al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol.30(9), 1849–1854 (2010).
   PubMed Web of Science ®Google Scholar
• Pedersen ER , UelandT, SeifertRet al. Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis212(2), 644–649 (2010).
   PubMed Web of Science ®Google Scholar
• Yang Q , LuS, ChenYet al. Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. Clin. Cardiol.34(7), 447–453 (2011).
   PubMed Web of Science ®Google Scholar
• Esteghamati A , AflatoonianM, RadMVet al. Association of osteoprotegerin with peripheral artery disease in patients with Type 2 diabetes. Arch. Cardiovasc. Dis.108(8–9), 412–419 (2015).
   PubMed Web of Science ®Google Scholar
• Gravallese EM . Osteopontin: a bridge between bone and the immune system. J. Clin. Invest.112(2), 147–149 (2003).
   PubMed Web of Science ®Google Scholar
• Gadeau AP , CampanM, MilletD, CandresseT, DesgrangesC. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler. Thromb.13(1), 120–125 (1993).
   PubMedGoogle Scholar
• Scatena M , LiawL, GiachelliCM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol.27(11), 2302–2309 (2007).
   PubMed Web of Science ®Google Scholar
• Wolak T . Osteopontin – a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis236(2), 327–337 (2014).
   PubMed Web of Science ®Google Scholar
• Bjerre M , PedersenSH, MøgelvangRet al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur. J. Prev. Cardiol.20(6), 922–929 (2013).
   PubMed Web of Science ®Google Scholar
• Kato R , MomiyamaY, OhmoriRet al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ. J.73(1), 152–157 (2009).
   PubMed Web of Science ®Google Scholar
• Georgiadou P , IliodromitisEK, KolokathisFet al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur. J. Clin. Invest.40(4), 288–293 (2010).
   PubMed Web of Science ®Google Scholar
• Ueland T , WilsonSG, AmirulIslam FMet al. A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clin. Endocrinol. (Oxf).71(6), 828–833 (2009).
   PubMed Web of Science ®Google Scholar
• Genre F , López-MejíasR, García-BermúdezMet al. Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis. PLoS ONE9(9), e106823 (2014).
   PubMed Web of Science ®Google Scholar
• Song DH , ZhouPZ, XiuXL, ZhouGH, SunYX, SongC. Relationships of OPG genetic polymorphisms with susceptibility to cardiovascular disease: a meta-analysis. Med. Sci. Monit.22, 1223–1231 (2016).
   PubMed Web of Science ®Google Scholar
• Jing M , LiB, HouXet al. OPN gene polymorphism and the serum OPN levels confer the susceptibility and prognosis of ischemic stroke in Chinese patients. Cell. Physiol. Biochem.32(6), 1798–1807 (2013).
   PubMedGoogle Scholar
• Lin JF , WuS, JuangJJet al. IL1RL1 single nucleotide polymorphism predicts sST2 level and mortality in coronary and peripheral artery disease. Atherosclerosis257, 71–77 (2017).
   PubMed Web of Science ®Google Scholar
• Tousoulis D , SiasosG, ManiatisKet al. Novel biomarkers assessing the calcium deposition in coronary artery disease. Curr. Med. Chem.19(6), 901–920 (2012).
   PubMed Web of Science ®Google Scholar
• Tousoulis D , SiasosG, ManiatisKet al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int. J. Cardiol.167(5), 1924–1928 (2013).
   PubMed Web of Science ®Google Scholar
• Røysland R , BonacaMP, OmlandTet al. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart98(10), 786–791 (2012).
   PubMed Web of Science ®Google Scholar
• Koshikawa M , AizawaK, KasaiHet al. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology60(1), 42–45 (2009).
   PubMed Web of Science ®Google Scholar
• Niu Y , ZhangW, YangZet al. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with Type 2 diabetes. BMC. Cardiovasc. Disord.15(1), 86 (2015).
   PubMedGoogle Scholar
• Liu W , GeS, LiuYet al. Polymorphisms in three genes are associated with hemorrhagic stroke. Brain. Behav.5(11), e00395 (2015).
   PubMed Web of Science ®Google Scholar
• Biscetti F , GiovanniniS, StrafaceGet al. RANK/RANKL/OPG pathway: genetic association with history of ischemic stroke in Italian population. Eur. Rev. Med. Pharmacol. Sci.20(21), 4574–4580 (2016).
   PubMed Web of Science ®Google Scholar
• Celczyńska Bajew L , HorstSikorska W, BychowiecB, WykrętowiczA, WesołyJ, MichalakM. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol. Pol.69(6), 573–578 (2011).
   PubMed Web of Science ®Google Scholar
• Song DH , ZhouPZ, XiuXL, ZhouGH, SunYX, SongC. Relationships of OPG genetic polymorphisms with susceptibility to cardiovascular disease: a meta-analysis. Med. Sci. Monit.22, 1223–1231 (2016).
   PubMed Web of Science ®Google Scholar
• Mu G , WangH, CaiZ, JiH. OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort. Cell. Physiol. Biochem.32(1), 171–179 (2013).
   PubMedGoogle Scholar
• Mi Y , RenK, DaiF, ZhuL, FengN. OPN gene polymorphisms, rs17524488 GG/G, rs11730582 T/C, and rs9138 C/A, and cancer risk in a Chinese population. Sci. Rep.5, 14164 (2015).
   PubMed Web of Science ®Google Scholar
• Hou X , HuZ, HuangXet al. Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J. Mol. Med. (Berl).92(5), 487–495 (2014).
   PubMed Web of Science ®Google Scholar
• Kim JG , KimJH, KimJYet al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause14(5), 913–918 (2007).
   PubMed Web of Science ®Google Scholar
• Omar HS , ShakerOG, NassarYH, MarzoukSA, ElMarzoukyMS. The association between RANKL and osteoprotegerin gene polymorphisms with breast cancer. Mol. Cell. Biochem.403(1–2), 219–229 (2015).
   PubMed Web of Science ®Google Scholar
• Xue JB , ZhanXL, WangWJ, YanYG, LiuC. OPG rs2073617 polymorphism is associated with upregulated OPG protein expression and an increased risk of intervertebral disc degeneration. Exp. Ther. Med.12(2), 702–710 (2016).
   PubMed Web of Science ®Google Scholar
• Jono S , IkariY, ShioiAet al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation106(10), 1192–1194 (2002).
   PubMed Web of Science ®Google Scholar
• Toffoli B , PickeringRJ, TsorotesDet al. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis218(1), 61–68 (2011).
   PubMed Web of Science ®Google Scholar
• Lawrie A , WatermanE, SouthwoodMet al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am. J. Pathol.172(1), 256–264 (2008).
   PubMed Web of Science ®Google Scholar
• Mosheimer BA , KaneiderNC, FeistritzerCet al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab.90(5), 2964–2971 (2005).
   PubMed Web of Science ®Google Scholar
• Zauli G , CoralliniF, BossiFet al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood110(2), 536–543 (2007).
   PubMed Web of Science ®Google Scholar
• Ueland T , YndestadA, ØieEet al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation111(19), 2461–2468 (2005).
   PubMed Web of Science ®Google Scholar
• Arnlöv J , EvansJC, BenjaminEJet al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart92(10), 1514–1515 (2006).
   PubMed Web of Science ®Google Scholar
• Carbone F , MontecuccoF. Novel cardiovascular risk biomarkers in carotid atherogenesis. Biomark. Med.12(10), 1065–1067 (2018).
   PubMed Web of Science ®Google Scholar
• Parker DM , BrownJR. Biomarkers for the prediction of cardiac readmission. Biomark. Med.13(2), 55–58 (2019).
   PubMed Web of Science ®Google Scholar
• Serra R , IelapiN, BarbettaA, AndreucciM, de FranciscisS. Novel biomarkers for cardiovascular risk. Biomark. Med.12(9), 1015–1024 (2018).
   PubMed Web of Science ®Google Scholar
• Oikonomou E , VogiatziG, TsalamandrisSet al. Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction. Biomark. Med.12(7), 783–797 (2018).
   PubMed Web of Science ®Google Scholar
• Chiba S , OkamotoH, KonSet al. Development of atherosclerosis in osteopontin transgenic mice. Heart. Vessels.16(3), 111–117 (2002).
   PubMed Web of Science ®Google Scholar
• Bruemmer D , CollinsAR, NohGet al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J. Clin. Invest.112(9), 1318–1331 (2003).
   PubMed Web of Science ®Google Scholar
• Liu J , RenY, KangL, ZhangL. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int. J. Mol. Med.33(5), 1341–1347 (2014).
   PubMed Web of Science ®Google Scholar